Updated: 22nd July 2026
Reviewed by: David Small BSc (Hons), MSc, MTOPRA (Founder and CEO)
Why Understanding the EU Medical Device Regulatory Roadmap Matters
Bringing a medical device to the European market involves far more than obtaining CE marking. Under the EU Medical Device Regulation (EU MDR 2017/745), manufacturers are responsible for demonstrating that their devices are safe, perform as intended and comply with a comprehensive set of regulatory requirements throughout their entire lifecycle.
For many organisations, particularly start-ups and first-time manufacturers, navigating these requirements can feel overwhelming. Questions often arise about where to begin, which activities should be completed first and how different elements of the regulatory process fit together. Decisions made early in development—such as determining whether a product is a medical device, selecting the correct classification or implementing an appropriate Quality Management System—can significantly influence the complexity, cost and timescales of obtaining CE marking.
Understanding the regulatory roadmap allows manufacturers to approach compliance in a structured and logical way. Rather than treating each requirement as a separate task, the roadmap demonstrates how activities such as Risk Management, Clinical Evaluation, Technical Documentation, conformity assessment and Post-Market Surveillance are interconnected and collectively support regulatory compliance.
This guide provides a high-level overview of the key stages involved in bringing a medical device to the European market under the EU MDR. It is designed to help manufacturers understand the overall regulatory journey and identify the detailed guidance they may need at each stage of product development and commercialisation.
Starting Your MDR Journey?
This roadmap article outlines the key stages of medical device compliance under Regulation (EU) 2017/745. For a complete overview of MDR requirements, including classification, Article 10 obligations, GSPRs, clinical evaluation, technical documentation, UDI, EUDAMED and CE marking, explore our EU MDR for Beginners Guide.
Step 1 – Determine Whether Your Product Is a Medical Device
Before considering device classification, Technical Documentation or CE marking, manufacturers must first determine whether their product meets the definition of a medical device under the EU Medical Device Regulation (EU MDR 2017/745). This is the foundation of every regulatory strategy, as products that are not considered medical devices are not subject to the MDR.
Under Article 2 of the MDR, a medical device is any instrument, apparatus, appliance, software, implant, reagent, material or other article intended by the manufacturer to be used for a medical purpose, such as diagnosing, preventing, monitoring, predicting, treating or alleviating disease or injury. Unlike medicinal products, medical devices achieve their principal intended action by means other than pharmacological, immunological or metabolic action, although these mechanisms may support their function.
Determining whether a product qualifies as a medical device requires careful consideration of several factors, including its intended purpose, the claims made by the manufacturer, its mode of action and how it will be used in practice. Products that sit on the boundary between medical devices and cosmetics, food supplements, medicinal products or general wellness products often require particularly careful assessment.
Making the wrong determination at the beginning of development can have significant consequences. If a product is incorrectly considered to fall outside the scope of the MDR, manufacturers may invest considerable time and resources before discovering that the product requires CE marking and full regulatory compliance. Conversely, treating a non-medical product as a medical device can introduce unnecessary cost and regulatory burden.
For this reason, determining whether your product is a medical device should always be the first step in your regulatory roadmap. Establishing the correct regulatory status from the outset provides a solid foundation for classification, conformity assessment and the remainder of the compliance process.
Step 2 – Classify Your Medical Device
Once you have established that your product is a medical device, the next step is determining its classification under the EU Medical Device Regulation (EU MDR 2017/745). Classification is one of the most important decisions in the regulatory process because it determines the level of regulatory scrutiny your device will receive and influences almost every subsequent stage of the compliance journey.
The MDR classifies medical devices according to the potential risks they present to patients and users. Devices are categorised as Class I, Class IIa, Class IIb or Class III using the classification rules set out in Annex VIII of the Regulation. Factors such as the intended purpose, duration of use, degree of invasiveness, whether the device is active or non-active, and the part of the body with which it interacts all contribute to determining the appropriate classification.
The device classification affects numerous regulatory obligations, including:
- Whether a Notified Body must be involved.
- The conformity assessment route that must be followed.
- The level of Technical Documentation required.
- Clinical Evaluation expectations.
- Post-Market Surveillance requirements.
- The evidence required to demonstrate compliance with the General Safety and Performance Requirements (GSPRs).
For example, many non-sterile, non-measuring Class I devices can be self-certified by the manufacturer, whereas Class IIa, IIb and III devices generally require assessment by a Notified Body before CE marking can be obtained. Higher-risk devices also require increasingly robust clinical evidence and more extensive regulatory documentation.
Because the classification rules can be complex, particularly for software, implantable devices and products incorporating novel technologies, manufacturers should document the rationale behind their classification decision. A well-supported classification assessment can help avoid delays during conformity assessment and provides clear justification should questions arise from regulators or Notified Bodies.
Selecting the correct classification at an early stage enables manufacturers to develop an appropriate regulatory strategy, allocate resources effectively and plan realistic timelines for bringing their device to market.
Need Help Classifying Your Medical Device?
Correct classification is one of the most important decisions in the regulatory journey, as it determines the conformity assessment route, Technical Documentation requirements, Clinical Evaluation expectations and the level of Notified Body involvement. Learn how the 22 classification rules in Annex VIII of the EU MDR are applied in our Complete Guide to EU Medical Device Classification.
Step 3 – Develop Your Regulatory Strategy
Once your medical device has been classified, the next step is to develop a clear regulatory strategy. A well-defined strategy provides a structured plan for achieving compliance with the EU Medical Device Regulation (EU MDR 2017/745), helping manufacturers understand which regulatory requirements apply to their device and how they will demonstrate conformity.
Rather than treating compliance as a series of independent tasks, a regulatory strategy brings together all aspects of the development process into a coordinated plan. This allows manufacturers to identify potential challenges early, allocate resources effectively and reduce the risk of delays during conformity assessment.
An effective regulatory strategy should consider:
- The device classification and applicable conformity assessment route.
- Whether a Notified Body is required.
- The regulatory evidence needed to support CE marking.
- Clinical Evaluation and, where applicable, Clinical Investigation requirements.
- Risk Management activities throughout the product lifecycle.
- Technical Documentation requirements under Annexes II and III.
- Quality Management System implementation.
- Timelines for development, testing and regulatory submission.
- Post-Market Surveillance and vigilance obligations following market launch.
Developing a regulatory strategy at an early stage also enables manufacturers to identify any additional requirements that may apply to their device. For example, software medical devices may need to demonstrate compliance with IEC 62304, products requiring usability engineering may need to apply IEC 62366-1, while devices incorporating biological materials may require additional biological evaluation in accordance with ISO 10993.
A documented regulatory strategy also provides a valuable framework for communication with internal teams, external consultants and Notified Bodies. By defining responsibilities, milestones and expected deliverables from the outset, manufacturers can better manage the regulatory process and avoid costly redesigns or documentation gaps later in development.
Ultimately, a robust regulatory strategy helps ensure that every stage of the product lifecycle is planned with compliance in mind, providing a clear pathway from concept through to CE marking and ongoing regulatory maintenance.
Step 4 – Implement a Quality Management System
A Quality Management System (QMS) provides the framework that enables manufacturers to consistently design, develop, manufacture and support medical devices in compliance with the EU Medical Device Regulation (EU MDR 2017/745). While the complexity of the system should be proportionate to the nature of the device and the organisation, every manufacturer must establish processes that ensure regulatory requirements are met throughout the product lifecycle.
Although the MDR does not explicitly require certification to ISO 13485, the Regulation expects manufacturers to operate an appropriate Quality Management System. ISO 13485:2016 is the internationally recognised standard for medical device quality management and is widely accepted as the most effective way of demonstrating compliance with these requirements. For manufacturers of Class IIa, IIb and III devices, a certified ISO 13485 Quality Management System is typically expected by Notified Bodies during conformity assessment.
An effective Quality Management System should cover all aspects of the organisation that influence product quality and regulatory compliance, including:
- Management responsibility and quality objectives.
- Design and development controls.
- Supplier qualification and purchasing controls.
- Document and record management.
- Risk Management integration.
- Complaint handling and vigilance.
- Corrective and Preventive Actions (CAPA).
- Internal audits and management reviews.
- Post-Market Surveillance activities.
- Continual improvement processes.
Rather than existing as a standalone requirement, the QMS underpins every stage of the regulatory roadmap. The procedures established within the system provide the foundation for activities such as Risk Management, Clinical Evaluation, Technical Documentation, production controls and post-market monitoring. As the device progresses from development to commercialisation, the Quality Management System ensures that regulatory processes remain controlled, documented and repeatable.
Implementing a robust QMS early in product development can significantly reduce compliance risks and streamline the journey towards CE marking. It also provides confidence to regulators, Notified Bodies and customers that the manufacturer has established appropriate controls to consistently deliver safe and effective medical devices.
Need to Build a Medical Device Quality Management System?
A compliant Quality Management System provides the framework for controlling design, development, suppliers, documentation, complaints, CAPA and Post-Market Surveillance. Learn how ISO 13485 supports regulatory compliance in our Complete Guide to ISO 13485 for Medical Device Manufacturers.
Step 5 – Design, Development and Risk Management
With a Quality Management System in place, manufacturers can begin the controlled design and development of their medical device. The EU MDR expects manufacturers to follow a structured development process that ensures the device is designed to meet its intended purpose while complying with all applicable regulatory requirements.
Design and development is far more than creating a functional product. Throughout the development lifecycle, manufacturers must generate objective evidence demonstrating that the device is safe, performs as intended and meets the General Safety and Performance Requirements (GSPRs) set out in Annex I of the MDR. Every design decision should be documented, justified and verified to create a clear record of how the device has evolved.
Risk Management is a fundamental part of this process and should begin at the earliest stages of development. ISO 14971:2019 provides the internationally recognised framework for identifying hazards, estimating and evaluating risks, implementing risk control measures and monitoring the effectiveness of those controls throughout the product lifecycle.
Effective Risk Management is an ongoing process that should consider:
- Hazards associated with the intended use and reasonably foreseeable misuse.
- Risks to patients, users and other persons.
- Design changes and their impact on device safety.
- Verification that implemented risk controls are effective.
- The balance between residual risks and the anticipated clinical benefits.
- Information gathered through Post-Market Surveillance to identify emerging risks.
Risk Management should not be treated as a standalone document completed at the end of development. Instead, it should be integrated into every stage of the design process, influencing design decisions, verification and validation activities, Clinical Evaluation and the preparation of Technical Documentation. As new information becomes available, the Risk Management File should be reviewed and updated to ensure it remains current throughout the device’s lifecycle.
By integrating design controls with effective Risk Management, manufacturers can identify potential issues early, reduce development risks and build the evidence needed to support conformity assessment and CE marking under the EU MDR.
Need Help with Medical Device Design and Development?
Successful medical device development requires more than creating a functional product. It involves integrating design controls, Risk Management, usability engineering, verification, validation and regulatory planning from the earliest stages of development. Learn more in our Complete Guide to Medical Device Design and Development.
Want to Understand ISO 14971 Risk Management?
Risk Management is a fundamental requirement of the EU MDR and should be integrated throughout the entire medical device lifecycle. Learn how to identify hazards, evaluate risks, implement effective risk controls and maintain a compliant Risk Management File in our Complete Guide to ISO 14971 Risk Management.
Step 6 – Clinical Evaluation and Supporting Evidence
Clinical Evaluation is a mandatory requirement for all medical devices under the EU Medical Device Regulation (EU MDR 2017/745), regardless of their classification. Its purpose is to demonstrate, through objective clinical evidence, that the device achieves its intended purpose, performs as claimed and that the benefits outweigh any identified risks.
Clinical Evaluation is not a one-time exercise carried out immediately before CE marking. Instead, it is a continuous process that begins during product development and is maintained throughout the entire lifecycle of the device. As new clinical data becomes available, manufacturers are expected to review and update their Clinical Evaluation to ensure it continues to reflect the current state of knowledge and post-market experience.
The evaluation typically considers a range of evidence, including:
- Published scientific literature.
- Clinical investigations, where required.
- Data from equivalent devices, where appropriate and sufficiently justified.
- Post-Market Surveillance and Post-Market Clinical Follow-up (PMCF) data.
- Risk Management outputs.
- Information relating to the current state of the art.
The level of clinical evidence required depends on factors such as the device classification, intended purpose, novelty and associated risks. Higher-risk and innovative devices generally require more extensive clinical evidence than well-established, lower-risk products. Regardless of the classification, manufacturers must be able to justify that sufficient evidence exists to support the safety, performance and clinical benefits of the device.
Clinical Evaluation also plays a central role in demonstrating compliance with the General Safety and Performance Requirements (GSPRs). The conclusions reached during the evaluation influence labelling, Instructions for Use, Risk Management activities and the Technical Documentation submitted during conformity assessment.
By establishing a robust Clinical Evaluation process early in development, manufacturers can identify evidence gaps, plan any additional clinical activities that may be required and build a strong body of evidence to support CE marking under the EU MDR.
Need to Understand Clinical Evaluation Under the EU MDR?
Clinical Evaluation is a mandatory requirement for all medical devices and demonstrates that a device is safe, performs as intended and delivers an acceptable benefit-risk profile. Learn how Clinical Evaluation Plans (CEPs), Clinical Evaluation Reports (CERs), clinical evidence and lifecycle updates support MDR compliance in our Complete Guide to Medical Device Clinical Evaluation.
Step 7 – Prepare Your Technical Documentation
Technical Documentation is the evidence that demonstrates your medical device complies with the requirements of the EU Medical Device Regulation (EU MDR 2017/745). Often referred to as the Technical File or Design Dossier, depending on the device and conformity assessment route, it brings together all of the documentation generated throughout the development process into a structured and traceable regulatory submission.
Rather than being a single document, Technical Documentation is a comprehensive collection of records that describe the device, explain how it was developed and demonstrate that it is safe, performs as intended and complies with the General Safety and Performance Requirements (GSPRs). The documentation must be maintained throughout the lifecycle of the device and updated whenever significant changes are made or new post-market information becomes available.
Under Annexes II and III of the MDR, Technical Documentation typically includes:
- Device description and specification.
- Information demonstrating compliance with the GSPRs.
- Design and manufacturing information.
- Risk Management documentation.
- Verification and validation evidence.
- Clinical Evaluation documentation.
- Labelling and Instructions for Use.
- Post-Market Surveillance planning and reports.
- Information on Unique Device Identification (UDI), where applicable.
The quality and organisation of the Technical Documentation are just as important as its content. Documents should be clearly structured, internally consistent and fully traceable, enabling regulators and Notified Bodies to understand how compliance has been demonstrated. Missing evidence, conflicting information or poorly organised files are among the most common reasons for delays during conformity assessment.
Technical Documentation should also be viewed as a living set of documents rather than a one-off submission for CE marking. As products evolve, standards are updated or post-market evidence is collected, manufacturers are expected to review and maintain their documentation to ensure it continues to reflect the current design, intended purpose and regulatory requirements.
Well-prepared Technical Documentation not only supports a smoother conformity assessment but also provides the foundation for maintaining regulatory compliance throughout the entire lifecycle of the medical device.
Need to Build a Compliant MDR Technical File?
Your Technical Documentation is the evidence that demonstrates compliance with the EU MDR and forms the basis of your conformity assessment. Learn how to structure an Annex II and Annex III compliant Technical File, organise supporting evidence and avoid common documentation deficiencies in our Complete Guide to Medical Device Technical Files.
Step 8 – Complete the Conformity Assessment and Obtain CE Marking
Before a medical device can be placed on the European market, manufacturers must demonstrate that it complies with the applicable requirements of the EU Medical Device Regulation (EU MDR 2017/745). This is achieved through the conformity assessment process, which verifies that the device meets the relevant regulatory, safety and performance requirements.
The conformity assessment route depends on the classification of the device. Many Class I devices can be self-certified by the manufacturer, provided they are not supplied sterile, do not have a measuring function and are not reusable surgical instruments. Higher-risk devices, including most Class IIa, Class IIb and Class III devices, require assessment by a Notified Body before CE marking can be granted.
During the conformity assessment process, manufacturers may be required to demonstrate compliance with areas such as:
- The General Safety and Performance Requirements (GSPRs).
- Technical Documentation prepared in accordance with Annexes II and III.
- Clinical Evaluation and supporting clinical evidence.
- Risk Management activities.
- Quality Management System implementation.
- Manufacturing and production controls.
- Post-Market Surveillance planning.
Where a Notified Body is involved, the assessment may include documentation reviews, Quality Management System audits and requests for additional evidence or clarification. The duration of the assessment varies depending on the complexity and classification of the device, the completeness of the documentation and the availability of the chosen Notified Body.
Once conformity has been successfully demonstrated, the manufacturer can prepare the EU Declaration of Conformity, affix the CE marking to the device and place it on the European market. However, CE marking should not be viewed as the end of the regulatory process. It represents the beginning of the manufacturer’s ongoing responsibilities, including maintaining Technical Documentation, monitoring device performance and ensuring continued compliance with the MDR.
Careful preparation throughout the earlier stages of the regulatory roadmap significantly improves the likelihood of a smooth conformity assessment, reducing delays and helping manufacturers bring their products to market more efficiently.
Need to Understand the Role of Notified Bodies?
Most Class IIa, Class IIb and Class III medical devices require assessment by a Notified Body before CE marking can be achieved. Learn how Notified Bodies are designated, when they are required, how to select the right organisation and what to expect during conformity assessment in our Complete Guide to Medical Device Notified Bodies.
Step 9 – Place Your Device on the Market
Once the conformity assessment has been successfully completed and the CE marking has been affixed, manufacturers can place their medical device on the European market. However, before commercialisation begins, several important regulatory obligations must be fulfilled to ensure the device is legally available for sale within the European Union.
Manufacturers are responsible for ensuring that all regulatory documentation is complete and that the device is supplied with the appropriate labelling and Instructions for Use. Depending on the classification and type of device, additional requirements such as Unique Device Identification (UDI), EUDAMED registration and the appointment of an EU Authorised Representative (for manufacturers located outside the European Union) may also apply.
Before placing a device on the market, manufacturers should ensure they have:
- Completed the applicable conformity assessment procedure.
- Prepared and signed the EU Declaration of Conformity.
- Affixed the CE marking in accordance with the MDR.
- Finalised compliant labelling and Instructions for Use.
- Assigned a Unique Device Identifier (UDI), where required.
- Registered the manufacturer and device in EUDAMED as the relevant modules become available and mandatory.
- Appointed an EU Authorised Representative if the manufacturer is based outside the European Union.
- Established systems for complaint handling, vigilance and Post-Market Surveillance.
Placing a device on the market is not simply the act of selling the product. Under the MDR, it refers to the first time a device is made available for distribution, consumption or use on the European market in the course of a commercial activity. Manufacturers remain legally responsible for the continued safety, performance and regulatory compliance of the device throughout its entire lifecycle.
Careful planning at this stage helps ensure a smooth product launch and reduces the risk of regulatory issues once the device reaches customers. By completing all pre-market obligations before commercialisation, manufacturers can begin supplying their devices with confidence while preparing for the ongoing responsibilities that follow after market entry.
Need to Understand Medical Device UDI Requirements?
Unique Device Identification (UDI) is a key requirement under the EU MDR, improving device traceability, patient safety and regulatory compliance. Learn how UDI-DI, UDI-PI, Basic UDI-DI, labelling and EUDAMED registration work together in our Complete Guide to Medical Device UDI.
Need to Understand EUDAMED?
EUDAMED is the European Commission's medical device database, supporting transparency, device registration, UDI, market surveillance and regulatory oversight under the EU MDR and IVDR. Learn how the six EUDAMED modules work, what information manufacturers must register and how EUDAMED supports lifecycle compliance in our Complete Guide to EUDAMED.
Step 10 – Maintain Compliance Through Post-Market Surveillance
Achieving CE marking is a significant milestone, but it is not the end of the regulatory journey. Under the EU Medical Device Regulation (EU MDR 2017/745), manufacturers are required to continually monitor the safety, performance and quality of their medical devices throughout their entire lifecycle. This ongoing process is known as Post-Market Surveillance (PMS).
A Post-Market Surveillance system enables manufacturers to proactively collect, analyse and evaluate information obtained from devices after they have been placed on the market. The objective is to confirm that the device continues to perform as intended, identify opportunities for improvement and detect any emerging risks that may require corrective action.
An effective PMS system should include activities such as:
- Collecting and reviewing customer feedback and complaints.
- Monitoring device performance and reliability.
- Investigating incidents and implementing corrective actions where necessary.
- Performing trend analysis to identify recurring issues.
- Updating the Risk Management File with post-market evidence.
- Reviewing and updating the Clinical Evaluation using new clinical data.
- Producing Periodic Safety Update Reports (PSURs) or Post-Market Surveillance Reports, where applicable.
- Conducting Post-Market Clinical Follow-up (PMCF) activities when required.
- Reporting serious incidents and Field Safety Corrective Actions (FSCAs) through the vigilance system.
Information gathered through Post-Market Surveillance should be used to continually improve the safety and performance of the device. Where new hazards or risks are identified, manufacturers may need to update their Technical Documentation, revise labelling or Instructions for Use, implement design changes or carry out additional clinical activities. Maintaining accurate and up-to-date documentation is therefore essential for demonstrating continued compliance with the MDR.
A well-managed PMS system also provides valuable evidence during regulatory inspections and Notified Body audits, demonstrating that the manufacturer has effective processes in place to monitor device performance after market launch and respond appropriately when issues arise.
Ultimately, regulatory compliance does not end when a device is placed on the market. It is an ongoing commitment that continues for as long as the device remains available to patients and healthcare professionals, ensuring that safety, performance and regulatory compliance are maintained throughout its entire lifecycle.
Need to Understand Post-Market Surveillance Under the EU MDR?
Post-Market Surveillance (PMS) is a mandatory requirement under the EU MDR and enables manufacturers to monitor real-world device safety, performance and regulatory compliance throughout the product lifecycle. Learn about PMS Plans, PMS Reports, PSURs, vigilance, trend reporting, PMCF and ongoing compliance in our Complete Guide to Medical Device Post-Market Surveillance.
Common Mistakes Manufacturers Make on the Regulatory Journey
Successfully navigating the EU Medical Device Regulation (EU MDR 2017/745) requires careful planning, thorough documentation and an understanding that regulatory compliance is an ongoing process rather than a single milestone. Many delays to CE marking occur not because manufacturers lack technical expertise, but because key regulatory activities were overlooked or completed too late in the development process.
Some of the most common mistakes include:
- Incorrectly determining whether a product is a medical device.
- Applying the wrong classification rules under Annex VIII.
- Leaving regulatory planning until product development is almost complete.
- Implementing a Quality Management System too late in the project.
- Treating Risk Management and Clinical Evaluation as standalone documents rather than continuous processes.
- Preparing incomplete or poorly structured Technical Documentation.
- Underestimating the time required for Notified Body assessment.
- Failing to establish robust Post-Market Surveillance procedures before market launch.
- Neglecting to keep Technical Documentation and Clinical Evaluation up to date after CE marking.
Taking a structured approach from the outset helps manufacturers avoid these common pitfalls. By following a logical regulatory roadmap, organisations can identify potential challenges earlier, generate the evidence needed to demonstrate compliance and reduce the risk of costly delays during conformity assessment.
Ultimately, successful compliance is achieved by viewing the MDR as a lifecycle framework rather than a one-time approval process. Manufacturers that integrate regulatory requirements into every stage of product development are far better positioned to achieve CE marking efficiently and maintain compliance throughout the lifetime of their medical devices.
Conclusion
Navigating the EU Medical Device Regulation (EU MDR 2017/745) can seem complex, but breaking the process into a series of structured steps makes the journey far more manageable. From determining whether your product is a medical device and selecting the correct classification, through implementing a Quality Management System, developing Technical Documentation and obtaining CE marking, each stage builds upon the previous one to demonstrate compliance with the Regulation.
While every medical device is different, the overall regulatory pathway remains the same. Manufacturers that plan their regulatory strategy early, generate evidence throughout development and maintain compliance after market launch are far more likely to achieve a smooth conformity assessment and avoid unnecessary delays.
This roadmap provides an overview of the key stages involved in bringing a medical device to the European market. Each step is supported by more detailed guidance covering topics such as medical device classification, ISO 13485, Risk Management, Clinical Evaluation, Technical Documentation, CE marking and Post-Market Surveillance. By understanding how these elements fit together, manufacturers can confidently navigate the regulatory process and build a strong foundation for long-term compliance under the EU MDR.
Frequently Asked Questions
The EU medical device regulatory roadmap is the sequence of activities manufacturers follow to achieve compliance with Regulation (EU) 2017/745 (EU MDR). It typically includes determining whether a product is a medical device, classifying the device, developing a regulatory strategy, implementing a Quality Management System, completing Risk Management and Clinical Evaluation, preparing Technical Documentation, obtaining CE marking and maintaining compliance through Post-Market Surveillance.
The first step is determining whether your product meets the definition of a medical device under Article 2 of the EU MDR. This assessment considers the product’s intended purpose, claims, mode of action and intended users. If the product falls within the scope of the Regulation, the manufacturer can then determine its classification and regulatory pathway.
Medical device classification determines the level of regulatory scrutiny a device receives. Devices are classified as Class I, Class IIa, Class IIb or Class III based on the classification rules in Annex VIII of the EU MDR. The classification influences the conformity assessment route, the need for a Notified Body, Clinical Evaluation requirements and the amount of Technical Documentation that must be prepared.
No. Many non-sterile, non-measuring Class I devices can be self-certified by the manufacturer. However, most Class IIa, Class IIb and Class III devices require a Notified Body to assess the manufacturer’s Quality Management System and Technical Documentation before CE marking can be obtained.
The EU MDR does not specifically require certification to ISO 13485, but manufacturers must establish an appropriate Quality Management System. ISO 13485 is the internationally recognised standard for medical device quality management and is widely accepted by regulators and Notified Bodies as the best framework for meeting these requirements.
Technical Documentation generally includes the device description, intended purpose, Risk Management documentation, General Safety and Performance Requirements (GSPR) evidence, verification and validation reports, Clinical Evaluation, manufacturing information, labelling, Instructions for Use, Post-Market Surveillance documentation and other records required under Annexes II and III of the EU MDR.
Clinical Evaluation demonstrates that a medical device is safe, performs as intended and delivers an acceptable benefit-risk profile based on clinical evidence. It is required for all medical devices and must be maintained throughout the product lifecycle using data from scientific literature, clinical investigations and Post-Market Surveillance activities.
After CE marking, manufacturers remain responsible for monitoring the safety and performance of their devices through Post-Market Surveillance. They must investigate complaints, report serious incidents where required, update Technical Documentation and Clinical Evaluation, and ensure continued compliance with the EU MDR throughout the product’s lifecycle.
The time required depends on factors such as the device classification, the completeness of the Technical Documentation, whether a Notified Body is required and the complexity of the product. For higher-risk devices, the conformity assessment process can take many months, making early regulatory planning essential.
Working with an experienced medical device regulatory consultancy can help manufacturers understand their obligations under the EU MDR, develop an appropriate regulatory strategy and prepare the documentation required for CE marking. Professional support can be particularly valuable for first-time manufacturers, complex technologies and higher-risk medical devices requiring Notified Body assessment.
References
This guide is based on the following legislation, international standards and official regulatory guidance relating to the regulatory pathway for medical devices under Regulation (EU) 2017/745 (MDR).
| Organisation | Reference | Why it's relevant |
|---|---|---|
| European Union | Regulation (EU) 2017/745 on Medical Devices (MDR) | Provides the complete legal framework governing the medical device regulatory pathway, including classification, conformity assessment, technical documentation, clinical evaluation, CE marking and post-market surveillance. |
| European Commission | MDCG Endorsed Documents and Other Guidance | Provides official Medical Device Coordination Group (MDCG) guidance supporting implementation of the MDR throughout the product lifecycle, from classification and technical documentation to post-market activities. |
| European Commission | Notified Bodies for Medical Devices | Explains the role and responsibilities of Notified Bodies responsible for conformity assessment and certification of medical devices requiring third-party review under the MDR. |
| European Commission | EUDAMED – European Database on Medical Devices | Provides official information on EUDAMED, supporting economic operator registration, device registration, UDI implementation, vigilance and market surveillance throughout the medical device lifecycle. |
| International Organization for Standardization (ISO) | ISO 13485:2016 – Medical Devices – Quality Management Systems – Requirements for Regulatory Purposes | Defines the internationally recognised Quality Management System requirements supporting the design, manufacture and ongoing regulatory compliance of medical devices. |
| International Organization for Standardization (ISO) | ISO 14971:2019 – Medical Devices – Application of Risk Management to Medical Devices | Provides the internationally recognised framework for identifying, evaluating and controlling risks throughout the medical device lifecycle, supporting regulatory compliance under the MDR. |
The medical device regulatory landscape continues to evolve through legislation, recognised standards and regulatory guidance. Manufacturers should always consult the latest published legislation, recognised standards and official guidance when planning and maintaining compliance throughout the medical device lifecycle.
Patient Guards Recent Posts
Cosmetic Product Safety Report (CPSR): A Complete Guide to UK Cosmetic Compliance
Before a cosmetic product can legally be placed on the UK market, manufacturers and Responsible Persons must demonstrate that it is safe for human use under normal or reasonably foreseeable conditions. The Cosmetic Product Safety Report (CPSR) is one of the most important regulatory documents required under the UK Cosmetics Regulation. This guide explains what a CPSR is, who can prepare one, what information it must contain, how it relates to the Product Information File (PIF) and how it supports legal cosmetic compliance.
IVDR PMPF Explained: A Complete Guide to Post-Market Performance Follow-up
Post-Market Performance Follow-up (PMPF) is a fundamental requirement under the EU In Vitro Diagnostic Regulation (IVDR), ensuring that manufacturers continually monitor the scientific validity, analytical performance and clinical performance of their in vitro diagnostic medical devices after CE marking. This guide explains IVDR PMPF requirements, PMPF Plans, PMPF Reports, Annex XIII expectations and how ongoing performance monitoring supports continued regulatory compliance throughout the device lifecycle.
IVDR Scientific Validity Explained: A Complete Guide for Manufacturers
Scientific Validity is the first pillar of IVDR Performance Evaluation and provides the scientific foundation demonstrating that an analyte or biomarker is associated with a specific clinical condition or physiological state. This guide explains Scientific Validity under Regulation (EU) 2017/746, including literature reviews, Scientific Validity Reports, Annex XIII requirements, evidence appraisal and how Scientific Validity supports successful CE marking.
Patient Guards Related Services
Patient Guards Regulatory Tools
Need Training?
Do you need training on Quality Management Systems or EU MDR/ EU IVDR? then check out our training courses.
